CN115243689A - 用于预防或治疗糖尿病和与之相关的代谢疾病的药物组合物 - Google Patents
用于预防或治疗糖尿病和与之相关的代谢疾病的药物组合物 Download PDFInfo
- Publication number
- CN115243689A CN115243689A CN202180019079.0A CN202180019079A CN115243689A CN 115243689 A CN115243689 A CN 115243689A CN 202180019079 A CN202180019079 A CN 202180019079A CN 115243689 A CN115243689 A CN 115243689A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- group
- inhibitor
- linear
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 71
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 41
- 208000030159 metabolic disease Diseases 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 claims abstract description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
- 201000010099 disease Diseases 0.000 claims abstract description 26
- 229940079593 drug Drugs 0.000 claims description 73
- 239000003814 drug Substances 0.000 claims description 73
- 239000003112 inhibitor Substances 0.000 claims description 34
- 229940122199 Insulin secretagogue Drugs 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 31
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 30
- 229940123208 Biguanide Drugs 0.000 claims description 30
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims description 30
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 30
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 29
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 229940126033 PPAR agonist Drugs 0.000 claims description 21
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 21
- 230000003287 optical effect Effects 0.000 claims description 18
- 239000012453 solvate Substances 0.000 claims description 18
- 229960004034 sitagliptin Drugs 0.000 claims description 17
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims description 17
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 16
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 14
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 12
- 229960003105 metformin Drugs 0.000 claims description 12
- 229960004346 glimepiride Drugs 0.000 claims description 11
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 11
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 claims description 10
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 claims description 10
- 229960001667 alogliptin Drugs 0.000 claims description 10
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 claims description 10
- 229960003834 dapagliflozin Drugs 0.000 claims description 10
- -1 elabevacrol Chemical compound 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 229960001729 voglibose Drugs 0.000 claims description 10
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 9
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 9
- 208000008589 Obesity Diseases 0.000 claims description 8
- 235000020824 obesity Nutrition 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 239000000556 agonist Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- XQSZLXRXPGLHLH-UHFFFAOYSA-N 3-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-5-propan-2-yl-1,2,4-oxadiazole Chemical compound CCC1=CN=C(N=C1)N1CCC(CCCOC2=CC(F)=C(C3=NOC(=N3)C(C)C)C(F)=C2)CC1 XQSZLXRXPGLHLH-UHFFFAOYSA-N 0.000 claims description 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 208000016097 disease of metabolism Diseases 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 6
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 claims 6
- 239000008280 blood Substances 0.000 abstract description 67
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 62
- 239000008103 glucose Substances 0.000 abstract description 62
- 210000004369 blood Anatomy 0.000 abstract description 58
- 230000000694 effects Effects 0.000 abstract description 18
- 230000037396 body weight Effects 0.000 abstract description 9
- 150000002632 lipids Chemical class 0.000 abstract description 5
- 241000699670 Mus sp. Species 0.000 description 41
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 31
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 31
- 229940125904 compound 1 Drugs 0.000 description 26
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 21
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 21
- 102100040918 Pro-glucagon Human genes 0.000 description 21
- 235000013305 food Nutrition 0.000 description 19
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 description 18
- 239000004480 active ingredient Substances 0.000 description 17
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 description 16
- 239000003446 ligand Substances 0.000 description 13
- 230000000291 postprandial effect Effects 0.000 description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 230000002218 hypoglycaemic effect Effects 0.000 description 10
- 235000020925 non fasting Nutrition 0.000 description 10
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 9
- 229960004580 glibenclamide Drugs 0.000 description 8
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- 238000011260 co-administration Methods 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 239000003925 fat Substances 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 6
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229960001381 glipizide Drugs 0.000 description 5
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 229960001052 streptozocin Drugs 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 3
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 3
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 3
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 description 3
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 3
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 3
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 3
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 3
- 238000011887 Necropsy Methods 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 3
- 229960002632 acarbose Drugs 0.000 description 3
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 229960001713 canagliflozin Drugs 0.000 description 3
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 3
- 229960003362 carbutamide Drugs 0.000 description 3
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 3
- 229950009226 ciglitazone Drugs 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 229950000269 emiglitate Drugs 0.000 description 3
- 229950002375 englitazone Drugs 0.000 description 3
- NWWORXYTJRPSMC-QKPAOTATSA-N ethyl 4-[2-[(2r,3r,4r,5s)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]ethoxy]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 NWWORXYTJRPSMC-QKPAOTATSA-N 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 229960000346 gliclazide Drugs 0.000 description 3
- 229960003468 gliquidone Drugs 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 229960002397 linagliptin Drugs 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 229960001110 miglitol Drugs 0.000 description 3
- 229960000698 nateglinide Drugs 0.000 description 3
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 3
- 229960005095 pioglitazone Drugs 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 229960002354 repaglinide Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229960004586 rosiglitazone Drugs 0.000 description 3
- 229960004937 saxagliptin Drugs 0.000 description 3
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 3
- 108010033693 saxagliptin Proteins 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229960002277 tolazamide Drugs 0.000 description 3
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 3
- 229960005371 tolbutamide Drugs 0.000 description 3
- 229950010728 trelagliptin Drugs 0.000 description 3
- IWYJYHUNXVAVAA-OAHLLOKOSA-N trelagliptin Chemical compound C=1C(F)=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 IWYJYHUNXVAVAA-OAHLLOKOSA-N 0.000 description 3
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 3
- 229960001641 troglitazone Drugs 0.000 description 3
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 3
- 229960001254 vildagliptin Drugs 0.000 description 3
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 3
- QKDRXGFQVGOQKS-CRSSMBPESA-N (2s,3r,4r,5s,6r)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](SC)O2)O)=CC=C1Cl QKDRXGFQVGOQKS-CRSSMBPESA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 101710163236 Glucose-dependent insulinotropic receptor Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229940122355 Insulin sensitizer Drugs 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- GSINGUMRKGRYJP-VZWAGXQNSA-N Remogliflozin Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N(C(C)C)N=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 GSINGUMRKGRYJP-VZWAGXQNSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960004111 buformin Drugs 0.000 description 2
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 229960001761 chlorpropamide Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229960003345 empagliflozin Drugs 0.000 description 2
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960003236 glisoxepide Drugs 0.000 description 2
- ZKUDBRCEOBOWLF-UHFFFAOYSA-N glisoxepide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NN2CCCCCC2)=N1 ZKUDBRCEOBOWLF-UHFFFAOYSA-N 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229950000991 ipragliflozin Drugs 0.000 description 2
- AHFWIQIYAXSLBA-RQXATKFSSA-N ipragliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 AHFWIQIYAXSLBA-RQXATKFSSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- CHHXEZSCHQVSRE-UHFFFAOYSA-N lobeglitazone Chemical compound C1=CC(OC)=CC=C1OC1=CC(N(C)CCOC=2C=CC(CC3C(NC(=O)S3)=O)=CC=2)=NC=N1 CHHXEZSCHQVSRE-UHFFFAOYSA-N 0.000 description 2
- 229950007685 lobeglitazone Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- BNYHRGTXRPWASY-UHFFFAOYSA-N nonylsulfonylurea Chemical compound CCCCCCCCCS(=O)(=O)NC(N)=O BNYHRGTXRPWASY-UHFFFAOYSA-N 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 229960003243 phenformin Drugs 0.000 description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940126844 remogliflozin Drugs 0.000 description 2
- MRWFZSLZNUJVQW-DEOSSOPVSA-N saroglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCN1C(C=2C=CC(SC)=CC=2)=CC=C1C MRWFZSLZNUJVQW-DEOSSOPVSA-N 0.000 description 2
- 229950006544 saroglitazar Drugs 0.000 description 2
- 229940126842 sergliflozin Drugs 0.000 description 2
- HFLCZNNDZKKXCS-OUUBHVDSSA-N sergliflozin Chemical compound C1=CC(OC)=CC=C1CC1=CC=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HFLCZNNDZKKXCS-OUUBHVDSSA-N 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229950005268 sotagliflozin Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QHFWGYNMVDIWCN-QHCPKHFHSA-N (1S)-1-[3-[2,6-difluoro-4-[3-[1-[5-[5-(2-methylpropyl)-1,2,4-oxadiazol-3-yl]pyrimidin-2-yl]piperidin-4-yl]propoxy]phenyl]-1,2,4-oxadiazol-5-yl]propan-1-ol Chemical compound CC[C@H](O)C1=NC(=NO1)C1=C(F)C=C(OCCCC2CCN(CC2)C2=NC=C(C=N2)C2=NOC(CC(C)C)=N2)C=C1F QHFWGYNMVDIWCN-QHCPKHFHSA-N 0.000 description 1
- NVNUATNPGWOLSD-NRFANRHFSA-N (1S)-1-[3-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-1,2,4-oxadiazol-5-yl]propan-1-ol Chemical compound C(C)C=1C=NC(=NC=1)N1CCC(CC1)CCCOC1=CC(=C(C(=C1)F)C1=NOC(=N1)[C@H](CC)O)F NVNUATNPGWOLSD-NRFANRHFSA-N 0.000 description 1
- IYOVCRMVLFWHBO-MRXNPFEDSA-N (2R)-1-[3-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-1,2,4-oxadiazol-5-yl]propan-2-ol Chemical compound C(C)C=1C=NC(=NC=1)N1CCC(CC1)CCCOC1=CC(=C(C(=C1)F)C1=NOC(=N1)C[C@@H](C)O)F IYOVCRMVLFWHBO-MRXNPFEDSA-N 0.000 description 1
- IYOVCRMVLFWHBO-INIZCTEOSA-N (2S)-1-[3-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-1,2,4-oxadiazol-5-yl]propan-2-ol Chemical compound CCC1=CN=C(N=C1)N1CCC(CCCOC2=CC(F)=C(C3=NOC(C[C@H](C)O)=N3)C(F)=C2)CC1 IYOVCRMVLFWHBO-INIZCTEOSA-N 0.000 description 1
- PAAPBNHWLWDNIO-MRXNPFEDSA-N (4R)-2-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-4-methyl-4,5-dihydro-1,3-oxazole Chemical compound C(C)C=1C=NC(=NC=1)N1CCC(CC1)CCCOC1=CC(=C(C(=C1)F)C=1OC[C@H](N=1)C)F PAAPBNHWLWDNIO-MRXNPFEDSA-N 0.000 description 1
- PAAPBNHWLWDNIO-INIZCTEOSA-N (4S)-2-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-4-methyl-4,5-dihydro-1,3-oxazole Chemical compound C(C)C=1C=NC(=NC=1)N1CCC(CC1)CCCOC1=CC(=C(C(=C1)F)C=1OC[C@@H](N=1)C)F PAAPBNHWLWDNIO-INIZCTEOSA-N 0.000 description 1
- WHVBVUXATDTJPF-MRXNPFEDSA-N (5R)-2-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-5-methyl-4,5-dihydro-1,3-oxazole Chemical compound C(C)C=1C=NC(=NC=1)N1CCC(CC1)CCCOC1=CC(=C(C(=C1)F)C=1O[C@@H](CN=1)C)F WHVBVUXATDTJPF-MRXNPFEDSA-N 0.000 description 1
- WHVBVUXATDTJPF-INIZCTEOSA-N (5S)-2-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-5-methyl-4,5-dihydro-1,3-oxazole Chemical compound C(C)C=1C=NC(=NC=1)N1CCC(CC1)CCCOC1=CC(=C(C(=C1)F)C=1O[C@H](CN=1)C)F WHVBVUXATDTJPF-INIZCTEOSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GWSFIVKYOUVPHN-UHFFFAOYSA-N 2-[2,6-difluoro-4-[3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]propoxy]phenyl]-5-ethyl-1,3,4-oxadiazole Chemical compound CCC1=NN=C(O1)C1=C(F)C=C(OCCCC2CCN(CC2)C2=NC(=NO2)C(C)C)C=C1F GWSFIVKYOUVPHN-UHFFFAOYSA-N 0.000 description 1
- UDGNEWYEALUHTR-UHFFFAOYSA-N 2-[2,6-difluoro-4-[3-[1-(5-fluoropyrimidin-2-yl)piperidin-4-yl]propoxy]phenyl]-5-propan-2-yl-1,3,4-thiadiazole Chemical compound FC1=C(C(=CC(=C1)OCCCC1CCN(CC1)C1=NC=C(C=N1)F)F)C=1SC(=NN=1)C(C)C UDGNEWYEALUHTR-UHFFFAOYSA-N 0.000 description 1
- MJKDDIURPLGUDQ-UHFFFAOYSA-N 2-[2,6-difluoro-4-[3-[1-(5-pentylpyrimidin-2-yl)piperidin-4-yl]propoxy]phenyl]-5-propan-2-yl-1,3,4-thiadiazole Chemical compound FC1=C(C(=CC(=C1)OCCCC1CCN(CC1)C1=NC=C(C=N1)CCCCC)F)C=1SC(=NN=1)C(C)C MJKDDIURPLGUDQ-UHFFFAOYSA-N 0.000 description 1
- XGHHGMXUKIQPLI-UHFFFAOYSA-N 2-[2,6-difluoro-4-[3-[1-(5-propylpyrimidin-2-yl)piperidin-4-yl]propoxy]phenyl]-5-propan-2-yl-1,3,4-thiadiazole Chemical compound FC1=C(C(=CC(=C1)OCCCC1CCN(CC1)C1=NC=C(C=N1)CCC)F)C=1SC(=NN=1)C(C)C XGHHGMXUKIQPLI-UHFFFAOYSA-N 0.000 description 1
- CINPEEAOORPOGU-UHFFFAOYSA-N 2-[2,6-difluoro-4-[3-[1-[5-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl]propoxy]phenyl]-5-propan-2-yl-1,3,4-thiadiazole Chemical compound CC(C)c1nnc(s1)-c1c(F)cc(OCCCC2CCN(CC2)c2ccc(cn2)C(F)(F)F)cc1F CINPEEAOORPOGU-UHFFFAOYSA-N 0.000 description 1
- SUNCUFFJEBISAN-UHFFFAOYSA-N 2-[2,6-difluoro-4-[3-[1-[5-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl]propoxy]phenyl]-5-ethyl-1,3,4-oxadiazole Chemical compound CCc1nnc(o1)-c1c(F)cc(OCCCC2CCN(CC2)c2ncc(cn2)C(F)(F)F)cc1F SUNCUFFJEBISAN-UHFFFAOYSA-N 0.000 description 1
- NXWOHNGJOWWVSY-UHFFFAOYSA-N 2-[2,6-difluoro-4-[3-[1-[5-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl]propoxy]phenyl]-5-methyl-1,3,4-oxadiazole Chemical compound Cc1nnc(o1)-c1c(F)cc(OCCCC2CCN(CC2)c2ncc(cn2)C(F)(F)F)cc1F NXWOHNGJOWWVSY-UHFFFAOYSA-N 0.000 description 1
- DVMZHYSKSOAXEC-UHFFFAOYSA-N 2-[2,6-difluoro-4-[3-[1-[5-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl]propoxy]phenyl]-5-propan-2-yl-1,3,4-oxadiazole Chemical compound CC(C)c1nnc(o1)-c1c(F)cc(OCCCC2CCN(CC2)c2ncc(cn2)C(F)(F)F)cc1F DVMZHYSKSOAXEC-UHFFFAOYSA-N 0.000 description 1
- JHACMVISVOOBLK-UHFFFAOYSA-N 2-[2,6-difluoro-4-[3-[1-[5-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl]propoxy]phenyl]-5-propan-2-yl-1,3,4-thiadiazole Chemical compound CC(C)c1nnc(s1)-c1c(F)cc(OCCCC2CCN(CC2)c2ncc(cn2)C(F)(F)F)cc1F JHACMVISVOOBLK-UHFFFAOYSA-N 0.000 description 1
- FGIJPSQKQLZHKV-UHFFFAOYSA-N 2-[3-[2,6-difluoro-4-[3-[1-[5-[5-(2-methylpropyl)-1,2,4-oxadiazol-3-yl]pyrimidin-2-yl]piperidin-4-yl]propoxy]phenyl]-1,2,4-oxadiazol-5-yl]-2-methylpropan-1-ol Chemical compound CC(C)CC1=NC(=NO1)C1=CN=C(N=C1)N1CCC(CCCOC2=CC(F)=C(C3=NOC(=N3)C(C)(C)CO)C(F)=C2)CC1 FGIJPSQKQLZHKV-UHFFFAOYSA-N 0.000 description 1
- LBYAHVRPVHCNBQ-UHFFFAOYSA-N 2-[3-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-1,2,4-oxadiazol-5-yl]ethanol Chemical compound CCC1=CN=C(N=C1)N1CCC(CCCOC2=CC(F)=C(C3=NOC(CCO)=N3)C(F)=C2)CC1 LBYAHVRPVHCNBQ-UHFFFAOYSA-N 0.000 description 1
- SPQCQGUIXURHAD-UHFFFAOYSA-N 2-[4-[3-[1-(5-chloropyrazin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-5-ethyl-1,3,4-oxadiazole Chemical compound ClC=1N=CC(=NC=1)N1CCC(CC1)CCCOC1=CC(=C(C(=C1)F)C=1OC(=NN=1)CC)F SPQCQGUIXURHAD-UHFFFAOYSA-N 0.000 description 1
- ZLBXHIBRQBLQFX-UHFFFAOYSA-N 2-[4-[3-[1-(5-chloropyrazin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-5-propan-2-yl-1,3,4-oxadiazole Chemical compound ClC=1N=CC(=NC=1)N1CCC(CC1)CCCOC1=CC(=C(C(=C1)F)C=1OC(=NN=1)C(C)C)F ZLBXHIBRQBLQFX-UHFFFAOYSA-N 0.000 description 1
- NQJUPDKTAVPBMI-UHFFFAOYSA-N 2-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-4,5-dihydro-1,3-oxazole Chemical compound C(C)C=1C=NC(=NC=1)N1CCC(CC1)CCCOC1=CC(=C(C(=C1)F)C=1OCCN=1)F NQJUPDKTAVPBMI-UHFFFAOYSA-N 0.000 description 1
- MCHMQXXWZBHHHF-UHFFFAOYSA-N 2-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-5,5-dimethyl-4H-1,3-oxazole Chemical compound C(C)C=1C=NC(=NC=1)N1CCC(CC1)CCCOC1=CC(=C(C(=C1)F)C=1OC(CN=1)(C)C)F MCHMQXXWZBHHHF-UHFFFAOYSA-N 0.000 description 1
- MBJLDAHWTCNJJO-UHFFFAOYSA-N 2-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-5-methyl-1,3,4-oxadiazole Chemical compound CCC1=CN=C(N=C1)N1CCC(CCCOC2=CC(F)=C(C3=NN=C(C)O3)C(F)=C2)CC1 MBJLDAHWTCNJJO-UHFFFAOYSA-N 0.000 description 1
- JUXRJGLKNXKQBA-UHFFFAOYSA-N 2-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-5-propan-2-yl-1,3,4-oxadiazole Chemical compound CCC1=CN=C(N=C1)N1CCC(CCCOC2=CC(F)=C(C3=NN=C(O3)C(C)C)C(F)=C2)CC1 JUXRJGLKNXKQBA-UHFFFAOYSA-N 0.000 description 1
- BGCIHCHYSVLCJR-UHFFFAOYSA-N 2-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-5-propan-2-yl-1,3,4-thiadiazole Chemical compound CCC1=CN=C(N=C1)N1CCC(CCCOC2=CC(F)=C(C3=NN=C(S3)C(C)C)C(F)=C2)CC1 BGCIHCHYSVLCJR-UHFFFAOYSA-N 0.000 description 1
- FQZRYOHEHIBMTA-UHFFFAOYSA-N 2-ethyl-5-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-1,3,4-oxadiazole Chemical compound CCC1=NN=C(O1)C1=C(F)C=C(OCCCC2CCN(CC2)C2=NC=C(CC)C=N2)C=C1F FQZRYOHEHIBMTA-UHFFFAOYSA-N 0.000 description 1
- LAEDLDRLTNJQAK-UHFFFAOYSA-N 3-[2,6-difluoro-4-[3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]propoxy]phenyl]-5-methyl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(=N1)N1CCC(CCCOC2=CC(F)=C(C3=NOC(C)=N3)C(F)=C2)CC1 LAEDLDRLTNJQAK-UHFFFAOYSA-N 0.000 description 1
- UTUATWFCXDRSPX-UHFFFAOYSA-N 3-[2,6-difluoro-4-[3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]propoxy]phenyl]-5-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NC(=NO1)C1=C(F)C=C(OCCCC2CCN(CC2)C2=NC(=NO2)C(C)C)C=C1F UTUATWFCXDRSPX-UHFFFAOYSA-N 0.000 description 1
- MBKDFITXGAMZOG-UHFFFAOYSA-N 3-[2,6-difluoro-4-[3-[1-(5-methoxypyrimidin-2-yl)piperidin-4-yl]propoxy]phenyl]-5-propan-2-yl-1,2,4-oxadiazole Chemical compound COc1cnc(nc1)N1CCC(CCCOc2cc(F)c(-c3noc(n3)C(C)C)c(F)c2)CC1 MBKDFITXGAMZOG-UHFFFAOYSA-N 0.000 description 1
- ABKBCILSRQHVJZ-UHFFFAOYSA-N 3-[2,6-difluoro-4-[3-[1-(5-pentylpyrimidin-2-yl)piperidin-4-yl]propoxy]phenyl]-5-propan-2-yl-1,2,4-oxadiazole Chemical compound FC1=C(C(=CC(=C1)OCCCC1CCN(CC1)C1=NC=C(C=N1)CCCCC)F)C1=NOC(=N1)C(C)C ABKBCILSRQHVJZ-UHFFFAOYSA-N 0.000 description 1
- NPBDNFUNMWHGKR-UHFFFAOYSA-N 3-[2,6-difluoro-4-[3-[1-(5-propan-2-yloxypyrimidin-2-yl)piperidin-4-yl]propoxy]phenyl]-5-propan-2-yl-1,2,4-oxadiazole Chemical compound FC1=C(C(=CC(=C1)OCCCC1CCN(CC1)C1=NC=C(C=N1)OC(C)C)F)C1=NOC(=N1)C(C)C NPBDNFUNMWHGKR-UHFFFAOYSA-N 0.000 description 1
- GACPRKUFORLXRY-UHFFFAOYSA-N 3-[2,6-difluoro-4-[3-[1-(5-propylpyrimidin-2-yl)piperidin-4-yl]propoxy]phenyl]-5-propan-2-yl-1,2,4-oxadiazole Chemical compound FC1=C(C(=CC(=C1)OCCCC1CCN(CC1)C1=NC=C(C=N1)CCC)F)C1=NOC(=N1)C(C)C GACPRKUFORLXRY-UHFFFAOYSA-N 0.000 description 1
- GCGPTOGNRDMEBF-UHFFFAOYSA-N 3-[2,6-difluoro-4-[3-[1-[5-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl]propoxy]phenyl]-5-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)c1nc(no1)-c1c(F)cc(OCCCC2CCN(CC2)c2ccc(cn2)C(F)(F)F)cc1F GCGPTOGNRDMEBF-UHFFFAOYSA-N 0.000 description 1
- MMSGXLNBAINNOD-UHFFFAOYSA-N 3-[2,6-difluoro-4-[3-[1-[5-(trifluoromethyl)pyrimidin-2-yl]piperidin-4-yl]propoxy]phenyl]-5-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)c1nc(no1)-c1c(F)cc(OCCCC2CCN(CC2)c2ncc(cn2)C(F)(F)F)cc1F MMSGXLNBAINNOD-UHFFFAOYSA-N 0.000 description 1
- JAVXGSMAWGBYPE-UHFFFAOYSA-N 3-[2,6-difluoro-4-[3-[1-[5-[5-(2-methylpropyl)-1,2,4-oxadiazol-3-yl]pyrimidin-2-yl]piperidin-4-yl]propoxy]phenyl]-5-ethyl-1,2,4-oxadiazole Chemical compound CCC1=NC(=NO1)C1=C(F)C=C(OCCCC2CCN(CC2)C2=NC=C(C=N2)C2=NOC(CC(C)C)=N2)C=C1F JAVXGSMAWGBYPE-UHFFFAOYSA-N 0.000 description 1
- GGDYSQGUWIDHQK-UHFFFAOYSA-N 3-[2,6-difluoro-4-[3-[1-[5-[5-(2-methylpropyl)-1,2,4-oxadiazol-3-yl]pyrimidin-2-yl]piperidin-4-yl]propoxy]phenyl]-5-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)CC1=NC(=NO1)C1=CN=C(N=C1)N1CCC(CCCOC2=CC(F)=C(C3=NOC(=N3)C(C)C)C(F)=C2)CC1 GGDYSQGUWIDHQK-UHFFFAOYSA-N 0.000 description 1
- PQKZMLKBZYPNCR-UHFFFAOYSA-N 3-[2-[4-[3-[3,5-difluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenoxy]propyl]piperidin-1-yl]pyrimidin-5-yl]-5-(2-methylpropyl)-1,2,4-oxadiazole Chemical compound CC(C)CC1=NC(=NO1)C1=CN=C(N=C1)N1CCC(CCCOC2=CC(F)=C(C3=NOC(C)=N3)C(F)=C2)CC1 PQKZMLKBZYPNCR-UHFFFAOYSA-N 0.000 description 1
- MXEDGZHGPIZYJV-UHFFFAOYSA-N 3-[2-[4-[3-[3,5-difluoro-4-[5-(methoxymethyl)-1,2,4-oxadiazol-3-yl]phenoxy]propyl]piperidin-1-yl]pyrimidin-5-yl]-5-(2-methylpropyl)-1,2,4-oxadiazole Chemical compound COCC1=NC(=NO1)C1=C(F)C=C(OCCCC2CCN(CC2)C2=NC=C(C=N2)C2=NOC(CC(C)C)=N2)C=C1F MXEDGZHGPIZYJV-UHFFFAOYSA-N 0.000 description 1
- VHOZGWQLDIJTBZ-UHFFFAOYSA-N 3-[2-[4-[3-[4-(5-butan-2-yl-1,2,4-oxadiazol-3-yl)-3,5-difluorophenoxy]propyl]piperidin-1-yl]pyrimidin-5-yl]-5-(2-methylpropyl)-1,2,4-oxadiazole Chemical compound CCC(C)C1=NC(=NO1)C1=C(F)C=C(OCCCC2CCN(CC2)C2=NC=C(C=N2)C2=NOC(CC(C)C)=N2)C=C1F VHOZGWQLDIJTBZ-UHFFFAOYSA-N 0.000 description 1
- IXDVPFMCUXKNPM-UHFFFAOYSA-N 3-[4-[3-[1-(5-bromopyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-5-propan-2-yl-1,2,4-oxadiazole Chemical compound BrC=1C=NC(=NC=1)N1CCC(CC1)CCCOC1=CC(=C(C(=C1)F)C1=NOC(=N1)C(C)C)F IXDVPFMCUXKNPM-UHFFFAOYSA-N 0.000 description 1
- IXASJBHWEPHWNB-UHFFFAOYSA-N 3-[4-[3-[1-(5-chloropyrazin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-5-propan-2-yl-1,2,4-oxadiazole Chemical compound ClC=1N=CC(=NC=1)N1CCC(CC1)CCCOC1=CC(=C(C(=C1)F)C1=NOC(=N1)C(C)C)F IXASJBHWEPHWNB-UHFFFAOYSA-N 0.000 description 1
- CNKVXYMRYQAKHS-UHFFFAOYSA-N 3-[4-[3-[1-(5-chloropyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-5-propan-2-yl-1,2,4-oxadiazole Chemical compound ClC=1C=NC(=NC=1)N1CCC(CC1)CCCOC1=CC(=C(C(=C1)F)C1=NOC(=N1)C(C)C)F CNKVXYMRYQAKHS-UHFFFAOYSA-N 0.000 description 1
- MMJQSTRSUVYHPY-UHFFFAOYSA-N 3-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-5-methyl-1,2,4-oxadiazole Chemical compound CCc1cnc(nc1)N1CCC(CCCOc2cc(F)c(-c3noc(C)n3)c(F)c2)CC1 MMJQSTRSUVYHPY-UHFFFAOYSA-N 0.000 description 1
- JCXQFHQUAMYOKV-UHFFFAOYSA-N 3-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-5-propyl-1,2,4-oxadiazole Chemical compound C(C)C=1C=NC(=NC=1)N1CCC(CC1)CCCOC1=CC(=C(C(=C1)F)C1=NOC(=N1)CCC)F JCXQFHQUAMYOKV-UHFFFAOYSA-N 0.000 description 1
- XUEZMHSYHPDUTG-UHFFFAOYSA-N 4-(3-phenoxypropyl)piperidine Chemical compound C1CNCCC1CCCOC1=CC=CC=C1 XUEZMHSYHPDUTG-UHFFFAOYSA-N 0.000 description 1
- ZTGIXDUFAHZZRP-UHFFFAOYSA-N 4-ethyl-2-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-1,3-thiazole Chemical compound C(C)C=1N=C(SC=1)C1=C(C=C(C=C1F)OCCCC1CCN(CC1)C1=NC=C(C=N1)CC)F ZTGIXDUFAHZZRP-UHFFFAOYSA-N 0.000 description 1
- MDXMSSMDQUSBEI-UHFFFAOYSA-N 5-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-N-propan-2-yl-1,3,4-oxadiazol-2-amine Chemical compound C(C)C=1C=NC(=NC=1)N1CCC(CC1)CCCOC1=CC(=C(C(=C1)F)C1=NN=C(O1)NC(C)C)F MDXMSSMDQUSBEI-UHFFFAOYSA-N 0.000 description 1
- QHOATOIQEYRGPU-UHFFFAOYSA-N 5-[4-[3-[4-(5,5-dimethyl-4H-1,3-oxazol-2-yl)-3,5-difluorophenoxy]propyl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC1(CN=C(O1)C1=C(C=C(OCCCC2CCN(CC2)C2=NC(=NO2)C(C)C)C=C1F)F)C QHOATOIQEYRGPU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- KTLUTNGUKNAZNM-UHFFFAOYSA-N C(C)(C)(C)C1=NC(=NO1)C1=C(C=C(C=C1F)OCCCC1CCN(CC1)C1=NC=C(C=N1)CC)F Chemical compound C(C)(C)(C)C1=NC(=NO1)C1=C(C=C(C=C1F)OCCCC1CCN(CC1)C1=NC=C(C=N1)CC)F KTLUTNGUKNAZNM-UHFFFAOYSA-N 0.000 description 1
- MJFXAMFNELOMJZ-UHFFFAOYSA-N C(C)C=1C=NC(=NC=1)N1CCC(CC1)CCCOC1=CC(=C(C(=C1)F)C1=NOC(=N1)C(CO)(C)C)F Chemical compound C(C)C=1C=NC(=NC=1)N1CCC(CC1)CCCOC1=CC(=C(C(=C1)F)C1=NOC(=N1)C(CO)(C)C)F MJFXAMFNELOMJZ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- XJUGHKROUSDQEB-UHFFFAOYSA-N ClC=1N=CC(=NC=1)N1CCC(CC1)CCCOC1=CC(=C(C(=C1)F)C=1OC(=NN=1)C)F Chemical compound ClC=1N=CC(=NC=1)N1CCC(CC1)CCCOC1=CC(=C(C(=C1)F)C=1OC(=NN=1)C)F XJUGHKROUSDQEB-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- DVJAMEIQRSHVKC-BDAKNGLRSA-N Dutogliptin Chemical compound OB(O)[C@@H]1CCCN1C(=O)CN[C@H]1CNCC1 DVJAMEIQRSHVKC-BDAKNGLRSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- MCIACXAZCBVDEE-CUUWFGFTSA-N Ertugliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@@]23O[C@@](CO)(CO2)[C@@H](O)[C@H](O)[C@H]3O)=CC=C1Cl MCIACXAZCBVDEE-CUUWFGFTSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LCDDAGSJHKEABN-MLGOLLRUSA-N Evogliptin Chemical compound C1CNC(=O)[C@@H](COC(C)(C)C)N1C(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F LCDDAGSJHKEABN-MLGOLLRUSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 229940100607 GPR119 agonist Drugs 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- 108091006065 Gs proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHSOLWOTCHFFBK-ZQGJOIPISA-N Luseogliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)S2)O)=C(OC)C=C1C WHSOLWOTCHFFBK-ZQGJOIPISA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000003673 Symporters Human genes 0.000 description 1
- 108090000088 Symporters Proteins 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- ZXOCGDDVNPDRIW-NHFZGCSJSA-N Tofogliflozin Chemical compound O.C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 ZXOCGDDVNPDRIW-NHFZGCSJSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- GQUOWAUUEXBBCB-LJQANCHMSA-N [(5R)-2-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-4,5-dihydro-1,3-oxazol-5-yl]methanol Chemical compound C(C)C=1C=NC(=NC=1)N1CCC(CC1)CCCOC1=CC(=C(C(=C1)F)C=1O[C@H](CN=1)CO)F GQUOWAUUEXBBCB-LJQANCHMSA-N 0.000 description 1
- GQUOWAUUEXBBCB-IBGZPJMESA-N [(5S)-2-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-4,5-dihydro-1,3-oxazol-5-yl]methanol Chemical compound C(C)C=1C=NC(=NC=1)N1CCC(CC1)CCCOC1=CC(=C(C(=C1)F)C=1O[C@@H](CN=1)CO)F GQUOWAUUEXBBCB-IBGZPJMESA-N 0.000 description 1
- FHBAMIGDSYJYOO-UHFFFAOYSA-N [3-[2,6-difluoro-4-[3-[1-(3-propan-2-yl-1,2,4-oxadiazol-5-yl)piperidin-4-yl]propoxy]phenyl]-1,2,4-oxadiazol-5-yl]methanol Chemical compound CC(C)C1=NOC(=N1)N1CCC(CCCOC2=CC(F)=C(C3=NOC(CO)=N3)C(F)=C2)CC1 FHBAMIGDSYJYOO-UHFFFAOYSA-N 0.000 description 1
- QCEBVPSCIQERKV-UHFFFAOYSA-N [3-[4-[3-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-1,2,4-oxadiazol-5-yl]methanol Chemical compound CCC1=CN=C(N=C1)N1CCC(CCCOC2=CC(F)=C(C3=NOC(CO)=N3)C(F)=C2)CC1 QCEBVPSCIQERKV-UHFFFAOYSA-N 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- LDXYBEHACFJIEL-HNNXBMFYSA-N anagliptin Chemical compound C=1N2N=C(C)C=C2N=CC=1C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N LDXYBEHACFJIEL-HNNXBMFYSA-N 0.000 description 1
- 229950009977 anagliptin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 235000021405 artificial diet Nutrition 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000021258 carbohydrate absorption Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229950003693 dutogliptin Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229950006535 ertugliflozin Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229950011259 evogliptin Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960001764 glibornuride Drugs 0.000 description 1
- RMTYNAPTNBJHQI-LLDVTBCESA-N glibornuride Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N[C@H]1[C@H](C2(C)C)CC[C@@]2(C)[C@H]1O RMTYNAPTNBJHQI-LLDVTBCESA-N 0.000 description 1
- GZKDXUIWCNCNBJ-UHFFFAOYSA-N glisolamide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NC2CCCCC2)=N1 GZKDXUIWCNCNBJ-UHFFFAOYSA-N 0.000 description 1
- 229950005319 glisolamide Drugs 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- QWEWGXUTRTXFRF-KBPBESRZSA-N gosogliptin Chemical compound C1C(F)(F)CCN1C(=O)[C@H]1NC[C@@H](N2CCN(CC2)C=2N=CC=CN=2)C1 QWEWGXUTRTXFRF-KBPBESRZSA-N 0.000 description 1
- 229950005754 gosogliptin Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229950004397 luseogliflozin Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- MKMPWKUAHLTIBJ-ISTRZQFTSA-N omarigliptin Chemical compound C1([C@H]2OC[C@@H](C[C@@H]2N)N2CC3=CN(N=C3C2)S(=O)(=O)C)=CC(F)=CC=C1F MKMPWKUAHLTIBJ-ISTRZQFTSA-N 0.000 description 1
- 229950000074 omarigliptin Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 108010027322 single cell proteins Proteins 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229940121377 sodium-glucose co-transporter inhibitor Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 description 1
- 229950000034 teneligliptin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229950006667 tofogliflozin Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明涉及一种用于预防或治疗糖尿病和选自与之相关的代谢疾病的至少一种疾病的药物组合物。根据本发明的药物组合物表现出优异的降低血糖水平、体重和血脂水平的效果。因此,该组合物可以有利地用于预防或治疗糖尿病和选自与之相关的代谢疾病的至少一种疾病。
Description
技术领域
本发明涉及一种用于预防或治疗糖尿病和与之相关的代谢疾病的药物组合物,其含有G蛋白偶联受体119(G protein coupled receptor 119,GPR119)配体和至少一种另一种机制的药物作为活性成分。
背景技术
糖尿病是一种慢性进行性疾病,其特征在于多因素引起的高血糖。因此,当单独使用单个药物时,很多情况下,根据症状不能达到预防或治疗糖尿病的充分效果。因此,尽管已有十几种不同机制的药物上市,仍然需要不断开发具有不同作用机制的降糖药物。
同时,与糖尿病相关的代谢疾病是糖尿病患者中的问题。具体地,与糖尿病相关的肥胖或血脂异常是一个问题。
发明内容
技术问题
本发明的一个目的在于提供一种药物组合物,当施用于受试者时其能够改善餐后和空腹血糖水平。
本发明的一个目的在于提供一种药物组合物,当施用于受试者时其表现出改善血脂浓度和减少体脂的效果。
本发明的一个目的在于提供一种药物组合物,其可以有利地用于预防或治疗糖尿病或与之相关的代谢疾病。
技术方案
根据本发明的一个实施方案,用于预防或治疗糖尿病或选自与之相关的代谢疾病的至少一种疾病的药物组合物可以包含由下式1表示的化合物、其药学上可接受的盐、其旋光异构体、其水合物、其溶剂化物或其混合物,和选自DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种。
[式1]
在上式1中,A可以为噁二唑基、二氢噁唑基、噻唑基或噻二唑基。以上A可以为未取代的或被选自以下的至少一个取代基取代:卤素原子、C1-C6直链或支链烷基和C1-C6直链或支链羟烷基。所述烷基或羟烷基可以各自独立地为未取代的或被卤素原子或C1-C6烷氧基取代。
B可以为吡啶基、嘧啶基、吡嗪基或噁二唑基。以上B可以为未取代的或被选自以下的至少一个取代基取代:卤素原子、C1-C6直链或支链烷基、C1-C6直链或支链羟烷基、C1-C6烷氧基和噁二唑基。所述C1-C6直链或支链烷基、C1-C6直链或支链羟烷基、C1-C6烷氧基或噁二唑基可以各自独立地为未取代的或被卤素、C1-C6烷基或C1-C6烷氧基取代。
X1和X2可以为F、Cl、Br或I。X1和X2可以彼此相同或不同。
R1至R3、R5和R6可以各自独立地为至少一个选自以下的取代基:氢原子、卤素原子、C1-C6直链或支链烷基和C1-C6直链或支链羟烷基。所述烷基或羟烷基可以各自独立地为未取代的或被卤素原子或C1-C6烷氧基取代。
以上R7至R11可以各自独立地被至少一个选自以下的取代基取代:氢原子、卤素原子、C1-C6直链或支链烷基、C1-C6直链或支链羟烷基、C1-C6烷氧基和噁二唑基。所述烷基、羟烷基、烷氧基或噁二唑基可以各自独立地为未取代的或被卤素原子、C1-C6烷基或C1-C6烷氧基取代。
X可以为F。
在上式1中,以上A可以为被C1-C6直链或支链烷基取代的噁二唑基,以上B可以为被C1-C6直链或支链烷基取代的嘧啶基,并且X可以为F。
在本实施方案中,术语“卤素”可以指氟、氯、溴或碘。
在一个实施方案中,除非另有说明,否则术语“烷基”可以指直链或支链烃残基。所述C1-C6烷基的示例可以包括甲基、乙基、丙基、异丙基、丁基、异丁基、戊基、己基等。
在一个实施方案中,除非另有说明,否则术语“烷氧基”可以包括具有如上定义的烷基的烷基-氧基团。所述C1-C6烷氧基的示例可以包括甲氧基、乙氧基、丙氧基、丁氧基、戊氧基等。
在一个实施方案中,除非另有说明,否则术语“杂环”或“杂环的”可以指包含1至3个选自N、O和S的杂原子的5至13元杂芳族或非芳族化合物。
在一个实施方案中,由上式1表示的化合物可以为至少一种具体选自以下化合物的化合物:
2-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-4,5-二氢噁唑,
(R)-2-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-4-甲基-4,5-二氢噁唑,
(S)-2-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-4-甲基-4,5-二氢噁唑,
(S)-2-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-5-甲基-4,5-二氢噁唑,
(R)-2-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-5-甲基-4,5-二氢噁唑,
2-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-5,5-二甲基-4,5-二氢噁唑,
(R)-(2-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-4,5-二氢噁唑-5-基)甲醇,
(S)-(2-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-4,5-二氢噁唑-5-基)甲醇,
(R)-3-(2-(4-(3-(3,5-二氟-4-(5-甲基-4,5-二氢噁唑-2-基)苯氧基)丙基)哌啶-1-基)嘧啶-5-基)-5-异丁基-1,2,4-噁二唑,
(R)-5-(4-(3-(3,5-二氟-4-(4-甲基-4,5-二氢噁唑-2-基)苯氧基)丙基)哌啶-1-基)-3-异丙基-1,2,4-噁二唑,
(S)-5-(4-(3-(3,5-二氟-4-(5-甲基-4,5-二氢噁唑-2-基)苯氧基)丙基)哌啶-1-基)-3-异丙基-1,2,4-噁二唑,
5-(4-(3-(4-(5,5-二甲基-4,5-二氢噁唑-2-基)-3,5-二氟苯氧基)丙基)哌啶-1-基)-3-异丙基-1,2,4-噁二唑,
3-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-5-甲基-1,2,4-噁二唑,
3-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-5-丙基-1,2,4-噁二唑,
3-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-5-异丙基-1,2,4-噁二唑,
5-(叔丁基)-3-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-1,2,4-噁二唑,
(3-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-1,2,4-噁二唑-5-基)甲醇,
2-(3-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-1,2,4-噁二唑-5-基)乙-1-醇,
(S)-1-(3-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-1,2,4-噁二唑-5-基)丙-1-醇,
(R)-1-(3-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-1,2,4-噁二唑-5-基)丙-2-醇,
(S)-1-(3-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-1,2,4-噁二唑-5-基)丙-2-醇,
2-(3-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-1,2,4-噁二唑-5-基)-2-甲基丙-1-醇,
3-(2,6-二氟-4-(3-(1-(5-丙基嘧啶-2-基)哌啶-4-基)丙氧基)苯基)-5-异丙基-1,2,4-噁二唑,
3-(2,6-二氟-4-(3-(1-(5-戊基嘧啶-2-基)哌啶-4-基)丙氧基)苯基)-5-异丙基-1,2,4-噁二唑,
3-(2,6-二氟-4-(3-(1-(5-(三氟甲基)嘧啶-2-基)哌啶-4-基)丙氧基)苯基)-5-异丙基-1,2,4-噁二唑,
3-(2,6-二氟-4-(3-(1-(5-甲氧基嘧啶-2-基)哌啶-4-基)丙氧基)苯基)-5-异丙基-1,2,4-噁二唑,
3-(2,6-二氟-4-(3-(1-(5-异丙氧基嘧啶-2-基)哌啶-4-基)丙氧基)苯基)-5-异丙基-1,2,4-噁二唑,
3-(4-(3-(1-(5-氯嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-5-异丙基-1,2,4-噁二唑,
3-(4-(3-(1-(5-溴嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-5-异丙基-1,2,4-噁二唑,
3-(2,6-二氟-4-(3-(1-(5-(5-异丁基-1,2,4-噁二唑-3-基)嘧啶-2-基)哌啶-4-基)丙氧基)苯基)-5-甲基-1,2,4-噁二唑,
3-(2,6-二氟-4-(3-(1-(5-(5-异丁基-1,2,4-噁二唑-3-基)嘧啶-2-基)哌啶-4-基)丙氧基)苯基)-5-乙基-1,2,4-噁二唑,
3-(2,6-二氟-4-(3-(1-(5-(5-异丁基-1,2,4-噁二唑-3-基)嘧啶-2-基)哌啶-4-基)丙氧基)苯基)-5-异丙基-1,2,4-噁二唑,
5-(仲丁基)-3-(2,6-二氟-4-(3-(1-(5-(5-异丁基-1,2,4-噁二唑-3-基)嘧啶-2-基)哌啶-4-基)丙氧基)苯基)-1,2,4-噁二唑,
3-(2,6-二氟-4-(3-(1-(5-(5-异丁基-1,2,4-噁二唑-3-基)嘧啶-2-基)哌啶-4-基)丙氧基)苯基)-5-(甲氧基甲基)-1,2,4-噁二唑,
(S)-1-(3-(2,6-二氟-4-(3-(1-(5-(5-异丁基-1,2,4-噁二唑-3-基)嘧啶-2-基)哌啶-4-基)丙氧基)苯基)-1,2,4-噁二唑-5-基)丙-1-醇,
2-(3-(2,6-二氟-4-(3-(1-(5-(5-异丁基-1,2,4-噁二唑-3-基)嘧啶-2-基)哌啶-4-基)丙氧基)苯基)-1,2,4-噁二唑-5-基)-2-甲基丙-1-醇,
3-(4-(3-(1-(5-氯吡嗪-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-5-异丙基-1,2,4-噁二唑,
3-(2,6-二氟-4-(3-(1-(5-(三氟甲基)吡啶-2-基)哌啶-4-基)丙氧基)苯基)-5-异丙基-1,2,4-噁二唑,
3-(2,6-二氟-4-(3-(1-(3-异丙基-1,2,4-噁二唑-5-基)哌啶-4-基)丙氧基)苯基)-5-甲基-1,2,4-噁二唑,
3-(2,6-二氟-4-(3-(1-(3-异丙基-1,2,4-噁二唑-5-基)哌啶-4-基)丙氧基)苯基)-5-异丙基-1,2,4-噁二唑,
(3-(2,6-二氟-4-(3-(1-(3-异丙基-1,2,4-噁二唑-5-基)哌啶-4-基)丙氧基)苯基)-1,2,4-噁二唑-5-基)甲醇,
2-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-5-甲基-1,3,4-噁二唑,
2-乙基-5-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-1,3,4-噁二唑,
2-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-5-异丙基-1,3,4-噁二唑,
5-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-N-异丙基-1,3,4-噁二唑-2-胺,
2-(2,6-二氟-4-(3-(1-(5-(三氟甲基)嘧啶-2-基)哌啶-4-基)丙氧基)苯基)-5-甲基-1,3,4-噁二唑,
2-(2,6-二氟-4-(3-(1-(5-(三氟甲基)嘧啶-2-基)哌啶-4-基)丙氧基)苯基)-5-乙基-1,3,4-噁二唑,
2-(2,6-二氟-4-(3-(1-(5-(三氟甲基)嘧啶-2-基)哌啶-4-基)丙氧基)苯基)-5-异丙基-1,3,4-噁二唑,
2-(4-(3-(1-(5-氯吡嗪-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-5-甲基-1,3,4-噁二唑,
2-(4-(3-(1-(5-氯吡嗪-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-5-乙基-1,3,4-噁二唑,
2-(4-(3-(1-(5-氯吡嗪-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-5-异丙基-1,3,4-噁二唑,
5-(4-(3-(3,5-二氟-4-(5-甲基-1,3,4-噁二唑-2-基)苯氧基)丙基)哌啶-1-基)-3-丙基-1,2,4-噁二唑,
5-(4-(3-(3,5-二氟-4-(5-乙基-1,3,4-噁二唑-2-基)苯氧基)丙基)哌啶-1-基)-3-丙基-1,2,4-噁二唑,
5-(4-(3-(3,5-二氟-4-(5-异丙基-1,3,4-噁二唑-2-基)苯氧基)丙基)哌啶-1-基)-3-丙基-1,2,4-噁二唑,
5-(4-(3-(3,5-二氟-4-(5-甲基-1,3,4-噁二唑-2-基)苯氧基)丙基)哌啶-1-基)-3-异丙基-1,2,4-噁二唑,
5-(4-(3-(4-(5-乙基-1,3,4-噁二唑-2-基)-3,5-二氟苯氧基)丙基)哌啶-1-基)-3-异丙基-1,2,4-噁二唑,
5-(4-(3-(3,5-二氟-4-(5-异丙基-1,3,4-噁二唑-2-基)苯氧基)丙基)哌啶-1-基)-3-异丙基-1,2,4-噁二唑,
5-(4-(3-(3,5-二氟-4-(5-甲基-1,3,4-噁二唑-2-基)苯氧基)丙基)哌啶-1-基)-3-(2,2,2-三氟乙基)-1,2,4-噁二唑,
3-(4-(3-(3,5-二氟-4-(5-异丙基-1,3,4-噁二唑-2-基)苯氧基)丙基)哌啶-1-基)-5-异丙基-1,2,4-噁二唑,
2-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-5-异丙基-1,3,4-噻二唑,
2-(2,6-二氟-4-(3-(1-(5-丙基嘧啶-2-基)哌啶-4-基)丙氧基)苯基)-5-异丙基-1,3,4-噻二唑,
2-(2,6-二氟-4-(3-(1-(5-戊基嘧啶-2-基)哌啶-4-基)丙氧基)苯基)-5-异丙基-1,3,4-噻二唑,
2-(2,6-二氟-4-(3-(1-(5-氟嘧啶-2-基)哌啶-4-基)丙氧基)苯基)-5-异丙基-1,3,4-噻二唑,
2-(2,6-二氟-4-(3-(1-(5-(三氟甲基)嘧啶-2-基)哌啶-4-基)丙氧基)苯基)-5-异丙基-1,3,4-噻二唑,
2-(2,6-二氟-4-(3-(1-(5-(三氟甲基)吡啶-2-基)哌啶-4-基)丙氧基)苯基)-5-异丙基-1,3,4-噻二唑,和
4-乙基-2-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)噻唑。
在一个实施方案中,由上式1表示的化合物可以为3-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-5-异丙基-1,2,4-噁二唑(以下称为化合物1)。
在一个实施方案中,药物组合物可以包含由上式1表示的化合物,和DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种。
DPPIV抑制剂可以为西格列汀、维格列汀、沙格列汀、利格列汀、吉格列汀、阿拉格列汀、特力列汀、阿格列汀、曲格列汀、奥格列汀、依格列汀、戈格列汀和度格列汀中的至少一种。
PPAR激动剂可以为曲格列酮、环格列酮、罗格列酮、吡格列酮、恩格列酮、埃拉贝诺、沙罗格列扎和洛贝格列酮中的至少一种。
SGLT2抑制剂可以为卡格列净、达格列净、恩格列净、埃格列净、依格列净、鲁格列净、瑞格列净、舍格列净、索格列净和托格列净中的至少一种。
胰岛素促分泌素可以为格列本脲、格列吡嗪、格列齐特、格列美脲、妥拉磺脲、甲苯磺丁脲、乙酰苯磺酰环己脲、氨磺丁脲、氯磺丙脲、格列波脲、格列喹酮、格列生脲、格列索脲、格列派特、格列吡脲、甘氨酰胺、格列戊脲、瑞格列奈和那格列奈中的至少一种。
双胍药物可以为二甲双胍、丁双胍和苯乙双胍中的至少一种。α-葡萄糖苷酶抑制剂可以为阿卡波糖、伏格列波糖、乙格列酯和米格列醇中的至少一种。
在一个实施方案中,药物组合物可以包含由上式1表示的化合物,和依格列汀、西格列汀、埃拉贝诺、达格列净、格列美脲、二甲双胍和伏格列波糖中的至少一种。
在一个实施方案中,药物组合物可以包含以上化合物1,和DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种。
在一个实施方案中,药物组合物可以包含以上化合物1,和依格列汀、西格列汀、埃拉贝诺、达格列净、格列美脲、二甲双胍和伏格列波糖中的至少一种。在一个实施方案中,代谢疾病可以为肥胖和血脂异常中的至少一种。
当在本说明书中描述药物组合物包含A和B时,药物组合物可以解释为是指包含A和B的组合物;分别包含作为单独的制剂的A和B的组合;或包含所述组合的组合物。因此,在本发明中,组合物可以与组合可互换使用。
药物组合物可以是一种包含以下者的药物组合物:由式1表示的化合物、其药学上可接受的盐、其旋光异构体、其水合物、其溶剂化物或其混合物,和选自DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种,分别作为单独的制剂或以组合制剂的形式包含全部。
药物组合物可以为单独的制剂的组合,或组合制剂。
药物组合物可以包含含有第一活性成分的第一隔室和含有第二活性成分的第二隔室。
第一活性成分可以为由式1表示的化合物、其药学上可接受的盐、其旋光异构体、其水合物、其溶剂化物或其混合物。第二活性成分可以包含选自DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种。
根据本发明的实施方案,在药物组合物中,含有第一活性成分的第一隔室和含有第二活性成分的第二隔室可以共同施用,因此药物组合物可以为用于共同施用的组合物。具体地,药物组合物可以为其中两种成分配制成单独的单位剂型的组合。在这种情况下,第一活性成分和第二活性成分可以作为单独的剂型共同施用。
在本发明的一个实施方案中,当向正常小鼠模型单次口服施用药物时,通过测量活性GLP-1的血液浓度和血糖浓度经过评价葡萄糖耐量改善的药效,发现一个实施方案的药物组合物在糖尿病的治疗和预防中是有效的。
在本发明的一个实施方案中,通过在提供特殊饮食诱导的高血糖、胰岛素抵抗或肥胖的小鼠模型中测量血糖、甘油三酯和体重,发现一个实施方案的药物组合物在治疗和预防糖尿病和与之相关的代谢疾病中是有效的。
更具体地,与当分别共同施用作为GPR119激动剂的由式1表示的化合物、其药学上可接受的盐、其旋光异构体、其水合物、其溶剂化物或其混合物,或DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂时相比,当施用根据一个实施方案的药物组合物时,确认了血GLP-1浓度上升,血糖下降,血浆甘油三酯浓度下降,体重下降。
在本发明中,由上式1表示的化合物的药学上可接受的盐的非限制性示例可以包括:无机酸盐如盐酸盐、溴酸盐、磷酸盐或硫酸盐;有机羧酸盐如乙酸盐、三氟乙酸盐、柠檬酸盐、马来酸盐、草酸盐、琥珀酸盐、苯甲酸盐、酒石酸盐、富马酸盐、扁桃酸盐、抗坏血酸盐或苹果酸盐,或磺酸盐如甲磺酸盐或对甲苯磺酸盐;碱金属盐如钠盐、钾盐或锂盐;已知能够形成其他药学上可接受的盐的各种酸式盐;等等。
根据一个实施方案的用于预防或治疗糖尿病或选自与之相关的代谢疾病的至少一种疾病的药物组合物可以以一般药物制剂的形式使用。药物制剂可以在施用时以各种口服和肠胃外剂型施用,并且可以根据使用方法不同地确定剂型。
如果将一个实施方案的药物组合物配制成数种口服和肠胃外剂型,则可以使用常用的辅料如填充剂、稀释剂、增量剂、粘合剂、保湿剂、崩解剂、表面活性剂等制备组合物。
用于口服施用的固体制剂可以包括片剂、丸剂、散剂、颗粒剂、胶囊剂等,这些固体制剂可以通过在药物组合物中混合至少一种辅料(例如淀粉、碳酸钙、蔗糖、乳糖、明胶等)来制备。此外,除了简单辅料以外还可以使用润滑剂如硬脂酸镁、滑石粉等。
此外,用于口服施用的液体制剂可以包括悬浮剂、内服液体、乳剂、糖浆剂等,但也可以包括除了水和液体石蜡(其是常用的简单稀释剂)以外的数种辅料,例如保湿剂、甜味剂、矫味剂、防腐剂等。
用于肠胃外施用的制剂可以包括无菌水溶液、非水溶剂、悬浮剂、乳剂、冻干制剂和栓剂。本文使用的非水溶剂和悬浮剂可以包括丙二醇、聚乙二醇、植物油如橄榄油、可注射酯如油酸乙酯等。本文使用的栓剂的基质可以包括维特普索尔(witepsol)、聚乙二醇、吐温(tween)61、可可脂、月桂醇、甘油明胶等。
此外,用于预防或治疗糖尿病或选自与之相关的代谢疾病的至少一种疾病的药物组合物可以具有代表约1至约1000mg的施用范围的有效量。施用量或摄入量可以以多种施用剂量和方法施用,如一天一次或一天数次,根据受试者的体重、年龄、性别、健康状况、饮食、施用时间、施用方法、排泄率和疾病的严重程度来分配组合物。
在本发明中,糖尿病可以包括1型糖尿病和2型糖尿病。1型糖尿病可以指以胰腺β细胞破坏和胰岛素绝对缺乏为特征的疾病,其是由遗传、环境和免疫学原因的相互作用而引起的。2型糖尿病可以指以胰岛素抵抗开始的疾病,其中细胞对胰岛素没有适当的反应,其可能由于体重过重和活动低下而引起。在2型糖尿病中,随着疾病的进展,可能会出现胰岛素缺乏。
一个实施方案的药物组合物可以包含由式1表示的化合物或具有与之相似的功能的活性成分,和选自胰岛素促分泌素、DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种。
本发明还可以提供一种用于预防或治疗糖尿病或选自与之相关的代谢疾病的至少一种疾病的方法,其包括向需要治疗的受试者施用治疗有效量的药物组合物,所述药物组合物包含由式1表示的化合物、其药学上可接受的盐、其旋光异构体、其水合物、其溶剂化物或其混合物,和选自DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种。
在本说明书中,术语“与之相关的代谢疾病”可以指与糖尿病共享一些病因的疾病,如肥胖或血脂异常,并且其很可能随着糖尿病的发作而容易出现。
在本说明书中,术语“至少一种”可以被解释为指示来源于多个配置的所有组合。例如,“A、B和C中的至少一种”可以解释为包括“A、B或C”、“选自A、B和C中的两种”和来源于“A、B和C”的所有组合。
在本说明书中,术语“需要治疗的受试者”可以指哺乳动物(包括人),术语“施用”可以指通过任何适当的方法向受试者提供预定物质。术语“治疗有效量”可以指诱导动物或人表现出被研究人员、兽医、医生或其他临床人员考虑的生物学或医学应答的活性成分或药物组合物的量,并且可以包括其用于诱导缓解待治疗的疾病或病症的症状的量。对于本领域技术人员显而易见的是,本发明的活性成分的治疗有效剂量和施用次数可以根据期望的效果而变化。
在一个实施方案中,本发明的药物组合物的施用途径可以是通过任何一般途径施用,只要它可以到达靶组织即可。
实施方案的药物组合物可以口服、腹膜内、静脉内、肌内、皮下、皮内、鼻内、肺内、直肠、腔内、腹膜内和鞘内施用,但不限于此。
实施方案的药物组合物可以一天一次或以确定的时间间隔一天至少两次施用。
一个实施方案的药物组合物可以单独使用或与手术、内分泌疗法、药物治疗和使用生物应答调节剂的方法组合使用,以预防和治疗糖尿病或选自与之相关的代谢疾病的至少一种疾病。
一个实施方案还可以提供一种用于预防或改善糖尿病或选自与之相关的代谢疾病的至少一种疾病的食品组合物,所述食品组合物包含作为活性成分的由上式1表示的化合物、其药学上可接受的盐、其旋光异构体、其水合物、其溶剂化物或其混合物,和选自DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种。
在一个实施方案中,术语“改善”可以指通过施用组合物使疾病好转或有利地转变的所有行为。
在一个实施方案中,术语“食品”可以指肉类、香肠、面包、巧克力、糖果、零食、甜食、比萨、方便面、其他面条、口香糖、乳制品(包括冰淇淋)、各种类型的汤、饮料、茶、保健饮料、酒精饮料、维生素复合物、保健功能食品、保健食品、保健补充食品等,包括传统意义上的所有食品。
术语“保健功能食品(functional food)”可以与特殊保健食品(food forspecial health use,FoSHU)为相同术语,是指具有高医疗效果和药效的食品,其经过加工以有效地显示除了提供营养之外的生物调节功能。在这种情况下,“功能(性)”可以指对人体的结构和功能而言,控制营养或获得健康用途的有益效果(如生理作用等)。
“保健食品(health food)”可以指与一般食品相比具有积极维持或增强健康的效果的食品,“保健补充食品(health supplement food)”可以指以保健补充为目的的食品。在一些情况下,保健功能食品、保健食品和保健补充食品的术语可以可互换使用。
本发明的食品可以通过本领域常规使用的方法来制备,并且在制备过程中可以加入本领域常规加入的原料和成分以制备食品。具体地,可以包括蛋白质、碳水化合物、脂肪、营养物、调味剂和矫味剂,并且所述碳水化合物的示例可以包括葡萄糖、果糖、麦芽糖、蔗糖、低聚糖、糊精、环糊精、木糖醇、山梨糖醇、赤藓醇、糖精或合成矫味剂,但不限于此。本发明的食品组合物可以制备成各种剂型而没有限制,只要该剂型被认为是食品即可。
本发明还可以提供一种用于预防或改善糖尿病或选自与之相关的代谢疾病的至少一种疾病的方法,其包括向需要改善的受试者施用食品组合物,所述食品组合物包含作为活性成分的由上式1表示的化合物、其药学上可接受的盐、其旋光异构体、其水合物、其溶剂化物或其混合物,和选自DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种。
本发明还可以提供一种用于预防或改善糖尿病或选自与之相关的代谢疾病的至少一种疾病的饲料组合物,所述饲料组合物包含作为活性成分的由上式1表示的化合物、其药学上可接受的盐、其旋光异构体、其水合物、其溶剂化物或其混合物,和选自DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种。
在本发明中,术语“饲料”可以指任何天然或人工饮食、膳食等、或所述膳食的成分,其将被牲畜食用或消化或适合于牲畜。饲料可以包含饲料添加剂或辅助饲料。
饲料的种类没有特别限制,可以使用本领域常用的饲料。饲料的非限制性示例可以包括:植物饲料如谷物、根茎果实、食品加工副产品、藻类、纤维、药物副产品、油和脂肪、淀粉、油粕粉、谷物副产品等;动物饲料如蛋白质、无机物、油和脂肪、矿物质、单细胞蛋白质、浮游动物、食品等。饲料可以单独使用或通过混合其中的至少两种来使用。
本发明还可以提供药物组合物用于预防或治疗糖尿病或选自与之相关的代谢疾病的至少一种疾病的用途,所述药物组合物包含作为活性成分的由上式1表示的化合物、其药学上可接受的盐、其旋光异构体、其水合物、其溶剂化物或其混合物,和选自DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种。
本发明还可以提供药物组合物在制备用于预防或治疗糖尿病或选自与之相关的代谢疾病的至少一种疾病的药物制剂中的用途,所述药物组合物包含作为活性成分的由上式1表示的化合物、其药学上可接受的盐、其旋光异构体、其水合物、其溶剂化物或其混合物,和选自DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种。
本发明还可以提供一种用于预防或治疗糖尿病或选自与之相关的代谢疾病的至少一种疾病的方法,其包括向需要治疗的受试者施用治疗有效量的药物组合物,所述药物组合物包含由上式1表示的化合物、其药学上可接受的盐、其旋光异构体、其水合物、其溶剂化物或其混合物,和选自DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种。
本发明还可以提供以下者的组合:由上式1表示的化合物、其药学上可接受的盐、其旋光异构体、其水合物、其溶剂化物或其混合物,和选自DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种。
本发明还可以提供一种用于预防或改善糖尿病或选自与之相关的代谢疾病的至少一种疾病的药物组合物,其包含与选自DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种组合的由上式1表示的化合物、其药学上可接受的盐、其旋光异构体、其水合物、其溶剂化物或其混合物。
在治疗方法、食品组合物、改善方法、饲料组合物、用途和组合中,由上式1表示的化合物具体可以为3-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-5-异丙基-1,2,4-噁二唑。
根据本发明的实施方案的药物组合物、治疗方法、食品组合物、改善方法、饲料组合物、用途和组合中的每一个中提及的事项在彼此不矛盾的情况下同样适用于每一个实施方案。
有利效果
根据本发明的药物组合物在施用于受试者时可以改善餐后和空腹血糖。
根据本发明的药物组合物在施用于受试者时可以表现出改善血脂浓度和减少体脂的效果。
因此,根据本发明的药物组合物可以有利地用于预防或治疗糖尿病或与之相关的代谢疾病。
附图说明
图1是显示当向正常小鼠单次口服施用药物时,药物增加葡萄糖负荷后5分钟活性GLP-1的峰值血液浓度和降低葡萄糖负荷后2小时餐后血糖水平的效果的图。
图2是显示当向正常小鼠单次口服施用药物时,药物对葡萄糖负荷后两小时餐后血糖的功效的图。
图3是显示当向HF/STZ糖尿病小鼠共同施用药物10周时,药物共同施用对非空腹和空腹血糖水平的功效的图。
图4是显示当向HF/STZ糖尿病小鼠共同施用药物10周时,药物共同施用对血浆甘油三酯浓度的功效的图。
图5是显示当向正常小鼠单次口服施用药物时,药物对葡萄糖负荷后两小时餐后血糖水平的功效的图。
图6是显示当向DIO小鼠单独施用和共同施用每种药物12周时的非空腹血糖水平的图。
图7是显示当向HF小鼠单独施用和共同施用每种药物3周时的总GLP-1的血浆浓度水平的图。
图8是显示当向HF小鼠单独施用和共同施用每种药物3周时的空腹血糖水平的图。
图9是显示当向HF小鼠单独施用和共同施用每种药物3周时,体重减轻率随时间的变化和身体成分改善的变化的水平的图。
图10是显示当向正常小鼠单次口服施用药物时,药物单独施用和组合施用对蔗糖负荷后2小时餐后血糖水平的功效的图。
具体实施方式
本发明的特征和优点以及用于实现它们的方法将参考下文详细描述的示例性实施方案而显而易见。然而,本发明不限于下文公开的示例性实施方案,而是将以各种不同的形式实施。在下文中,将提出以下示例性实施方案以更好地理解本发明,仅为了向本领域技术人员完整地说明本发明的范围而提供,因此本发明将仅由其权利要求的范围限定。
根据本发明的用于预防或治疗糖尿病或选自与之相关的代谢疾病的至少一种疾病的药物组合物可以包含由式1表示的化合物、其药学上可接受的盐、其旋光异构体、其水合物、其溶剂化物或其混合物,和选自DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种。
由式1表示的化合物可以为GPR119配体,G蛋白偶联受体119(GPR119)可以是属于A类的G蛋白偶联受体(G protein-coupled receptor,GPCR)之一。
GRP119可以被GRP119配体活化,通过G蛋白亚型中的Gαs产生cAMP,从而诱导细胞内信号传导。
GRP119可以在胰腺β细胞和小肠L细胞中具有高表达水平。因此,当通过施用一个实施方案的药物组合物活化胰腺的GPR119时,胰腺β细胞的胰岛素分泌可以增加,从而降低餐后血糖。因此,当GPR119被活化时,除了血糖控制以外,还可以实现降低血脂和体重的效果,从而有助于改善糖尿病以及与之相关的代谢疾病。
同时,当小肠的GPR119被活化时,可以增加小肠L细胞分泌的胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)。GLP-1可以表现出抑制餐后脂肪流入小肠血流的局部作用。
通常,GLP-1受体样作用可以通过高分子化合物(如肽配体)来调节。然而,由于根据一个实施方案的药物组合物包含GPR119配体(其为相对低分子量化合物),因此可以通过口服低分子量化合物来实现GLP-1受体样作用。
在一个实施方案的由式1表示的化合物中,卤素元素可以在4-(3-苯氧基丙基)哌啶的苯基部分的2位和6位上取代。因此,它可以与GPR119更敏感地反应,并且GPR119的活化程度可以比施用其他GPR119配体时明显更高。
一个实施方案的药物组合物除了由上式1表示的化合物以外,可以进一步包含选自DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡糖苷酶抑制剂中的至少一种。因此,一个实施方案的药物组合物可以施用至少两种不同机制的药物,以通过多种机制降低血糖,从而有效控制血糖。
目前应用于糖尿病患者的降血糖药可以包括二肽基肽酶IV(dipeptidylpeptidase IV,DPPIV)抑制剂、胰岛素增敏剂、通过抑制钠-葡萄糖协同转运蛋白2的机制促进尿葡萄糖排泄的钠葡萄糖协同转运蛋白2(sodium glucose co-transporter 2,SGLT2)抑制剂、胰岛素促分泌素、双胍药物(双胍)、α-葡萄糖苷酶抑制剂等。
二肽基肽酶IV(DPPIV)可以为通过从血液中GLP-1的N-末端去除两个氨基酸而使GLP-1失活的酶。GLP-1由GPR119配体诱导分泌,在转入血液后数分钟内可被DPPIV酶灭活。因此,当组合使用增加GLP-1分泌的GPR119配体和阻断GLP-1失活的DPPIV抑制剂时,可以延长活性GLP-1在血液中的作用持续时间以及β细胞GPR119活化的直接胰岛素分泌效果。因此,改善代谢疾病的药效可以是优异的。换言之,DPPIV抑制剂可以通过延长内源性GLP-1的生物学作用来促进胰岛素分泌,因此可以表现出餐后降血糖效果。
DPPIV抑制剂可以包括例如西格列汀(sitagliptin)、维格列汀(vildagliptin)、沙格列汀(saxagliptin)、利格列汀(linagliptin)、吉格列汀(gemigliptin)、阿拉格列汀(anagliptin)、特力列汀(teneligliptin)、阿格列汀(alogliptin)、曲格列汀(trelagliptin)、奥格列汀(omarigliptin)、依格列汀(evogliptin)、戈格列汀(gosogliptin)和度格列汀(dutogliptin)中的至少一种。
胰岛素增敏剂可以为用于活化过氧化物酶体增殖物活化受体(peroxisomeproliferator-activated receptor,PPAR)的药物。PPAR激动剂可以包括例如曲格列酮(troglitazone)、环格列酮(ciglitazone)、罗格列酮(rosiglitazone)、吡格列酮(pioglitazone)、恩格列酮(englitazone)、埃拉贝诺(elafibranor)、沙罗格列扎(saroglitazar)和洛贝格列酮(lobeglitazone)中的至少一种。
药物钠葡萄糖协同转运蛋白2(SGLT2)抑制剂可以通过以不依赖胰岛素的方式抑制肾脏对葡萄糖的重吸收来促进葡萄糖排泄。此外,它可以伴随着由于葡萄糖排泄而导致的热量损失引起的体重减轻。SGLT2抑制剂可以包括例如卡格列净(canagliflozin)、达格列净(dapagliflozin)、恩格列净(empagliflozin)、埃格列净(ertugliflozin)、依格列净(ipragliflozin)、鲁格列净(luseogliflozin)、瑞格列净(remogliflozin)、舍格列净(sergliflozin)、索格列净(sotagliflozin)和托格列净(tofogliflozin)中的至少一种。
胰岛素促分泌素可以包括磺酰脲类药物和非磺酰脲类药物。例如,磺脲类的胰岛素促分泌素可以包括格列本脲(glibenclamide,glyburide)、格列吡嗪(glipizide)、格列齐特(gliclazide)、格列美脲(glimepiride)、妥拉磺脲(tolazamide)、甲苯磺丁脲(tolbutamide)、乙酰苯磺酰环己脲(acetohexamide)、氨磺丁脲(carbutamide)、氯磺丙脲(chlorpropamide)、格列波脲(glibornuride)、格列喹酮(gliquidone)、格列生脲(glisentide)、格列索脲(glisolamide)、格列派特(glisoxepide)、格列吡脲(glyclopyamide)、甘氨酰胺(glycylamide)和格列戊脲(glipentide)中的至少一种。非磺酰脲结构的胰岛素促分泌素可以包括瑞格列奈(repaglinide)和那格列奈(nateglinide)中的至少一种。
双胍药物可以抑制肝脏中的糖异生。双胍药物可以包括例如二甲双胍、丁双胍和苯乙双胍中的至少一种。
α-葡糖苷酶抑制剂可以通过抑制在肠中将二糖分解成单糖的酶活性而表现出延迟碳水化合物吸收的作用。α-葡萄糖苷酶抑制剂可以包括例如阿卡波糖(acarbose)、伏格列波糖(voglibose)、乙格列酯(emiglitate)和米格列醇(miglitol)中的至少一种。
一个实施方案的药物组合物可以包含成分的复合。因此,当施用一个实施方案的药物组合物时,通过作用机制彼此不同的两种药物,不仅可以实现降血糖效果,还可以实现降低血脂和体重的效果。
因此,与单独施用各个成分的情况相比,它可以表现出治疗或预防糖尿病和与之相关的代谢疾病的优异效果。
在下文中,将参考实施例和比较例详细描述根据本发明的一个实施方案的药物组合物。
<实施例1>GPR119配体与DPPIV抑制剂的组合功效的确认
在正常小鼠中单剂量施用的功效的评价
向禁食至少16小时的7周龄ICR雄性小鼠单独施用化合物1、作为DDPIV抑制剂的西格列汀或依格列汀,或者施用化合物1与西格列汀和依格列汀之一的组合。在单独施用和共同施用中,向小鼠口服施用0.3mg/kg的化合物1、10mg/kg的西格列汀和0.2mg/kg的依格列汀。在药物施用后30分钟的时间点,以2g/kg/10ml口服加载葡萄糖溶液。
为了测量根据组合的活性GLP-1血浆浓度的变化,使用经DPPIV抑制剂预处理的容器分离葡萄糖负载后5分钟的血浆,使用GLP-1(Active)ELISA试剂盒(Millipore,Cat.EGLP-35K)对活性GLP-1的血浆浓度进行定量。为了评价药物对餐后血糖水平的反应,在葡萄糖激发后0、15、30、60、90和120分钟的时间点,使用Roche的AccuChek Active血糖仪测量从尾静脉收集的全血中的血糖水平。获得时间-血糖水平反应曲线。对于变化率,比较了仅施用溶剂的对照组的时间-血糖水平曲线下面积与药物施用组的时间-血糖水平曲线下面积。其结果示于图1和图2。
如图1所确认,与单独施用化合物1或西格列汀的组相比,当化合物1和作为DPPIV抑制剂的西格列汀组合施用时,活性GLP-1的血液浓度显著升高。此外,与单独施用化合物1或西格列汀的组相比,共同施用组中葡萄糖负荷后两小时的血糖水平也显著升高。
如图2所确认,当施用化合物1和作为另一种DPPIV抑制剂的依格列汀时,还表现出改善餐后血糖水平的协同效应。
在糖尿病小鼠中10周多剂量施用的功效的评价
向7周龄ICR雄性小鼠提供高脂肪饮食(Research Diets Inc.,D12492;60%kcal脂肪)持续3周。在第3周腹腔注射80mg/kg的链脲佐菌素(streptozotocin,STZ)后3周的时间点,将小鼠根据体重、血糖和血甘油三酯浓度分组。具体地,通过选择与正常小鼠相比非空腹血糖水平升高1SD(标准差)或更高且血浆甘油三酯水平升高2SD或更高的个体来进行分组。向选定组给予药物-饮食混合物,其中混合了100mg/kg/天的化合物1和150mg/kg/天的西格列汀。将混合物供应10周。之后,测量空腹血糖水平、非空腹血糖水平和血浆甘油三酯浓度。使用Roche的AccuChek Active血糖仪从尾静脉采集的血液中测量空腹和非空腹血糖。使用自动血液学分析仪(Konelab 20i)从非空腹尸检后收集的血浆中测量血浆甘油三酯浓度。
如图3所确认,与仅施用高脂肪饮食不施用混合药物的高脂肪/链脲佐菌素(HF/STZ)小鼠相比,当化合物1和西格列汀共同施用10周时,确认了空腹和非空腹血糖水平与正常小鼠的相似。换言之,在空腹和非空腹血糖水平方面均表现出优异的降血糖率。
如图4所确认,当共同施用化合物1和西格列汀时,在患有糖尿病和高甘油三酯血症的HF/STZ小鼠中表现出优异的降低血浆甘油三酯浓度的速率。特别地,当向小鼠共同施用化合物1和西格列汀时,确认了血浆甘油三酯浓度降低至与正常小鼠相当的水平,因为血浆甘油三酯浓度约为200(mg/dl)。
<实施例2>GPR119配体与SGLT2抑制剂或胰岛素促分泌素格列美脲的组合功效的确认
向禁食至少16小时的7周龄ICR雄性小鼠单独施用化合物1、作为SGLT抑制剂的达格列净或作为胰岛素促分泌素的格列美脲,或者施用化合物1与达格列净和格列美脲之一的组合。在单独或组合口服施用3mg/kg的化合物1、0.3mg/kg的作为SGLT2抑制剂的达格列净或0.1mg/kg的作为胰岛素促分泌素的格列美脲后30分钟的时间点,以2g/kg/10ml口服加载葡萄糖溶液。为了评价药物对餐后血糖水平的反应,在血液中葡萄糖激发后0、15、30、60、90和120分钟的时间点,使用Roche的AccuChek Active血糖仪测量从尾静脉收集的全血中的血糖水平。获得时间-血糖水平反应曲线。对于变化率,比较了仅施用溶剂的对照组的时间-血糖水平曲线下面积与药物施用组的时间-血糖水平曲线下面积。
如图5所确认,当共同施用两种药物时,降血糖功效比当单独施用时更显著地增加。
<实施例3>GPR119配体与PPAR激动剂的组合功效的确认
为了诱导胰岛素抵抗,向6周龄雄性C57BL/6J小鼠提供高脂肪、高果糖和高胆固醇的特殊饮食(Research Diets Inc.,D09100301)持续至少27周。制备了药物-饮食混合物,使得可以向饮食诱导的肥胖(diet-induced obese,DIO)且胰岛素抵抗小鼠单独或组合施用100mg/kg/天的化合物1和30mg/kg/天的作为PPAR激动剂的埃拉贝诺。将制备的药物-饮食混合物提供给小鼠持续12周。使用Roche的AccuChek Active血糖仪在药物施用后12周的时间点从尸检后收集的血浆中测量非空腹血糖水平。
如图6所确认,单独的化合物1在严重的胰岛素抵抗小鼠中没有表现出显著的降血糖效果,单独的埃拉贝诺由于改善了胰岛素抵抗表现出降血糖效果。然而,与单独使用每种药物相比,当两种药物组合使用时,确认了表现出显著优异的降血糖效果。
<实施例4>GPR119配体与双胍药物的组合功效的确认
向4周龄C57BL/6J雄性小鼠提供高脂肪饮食(Research Diets Inc.,D12492;60%kcal脂肪)持续10周以诱导胰岛素抵抗。在适应药物施用2周后,根据体重和体脂将小鼠分配到各组。化合物1单一疗法组以50mg/kg每天两次单独施用化合物1,二甲双胍单一疗法组以150mg/kg每天两次单独施用二甲双胍。共同施用组口服共同施用50mg/kg的化合物1和150mg/kg的二甲双胍,每天两次,持续3周。随时间测量体重直至第16天的施用的时间点,在最后一周通过使用Minispec LF90II NMR波谱仪(Bruker Optics,埃特林根,德国)依次测量身体成分。使用Roche的AccuChek Active血糖仪在施用的第2周禁食6小时后从尾静脉采集的全血中测量空腹血糖。施用3周后,进行非空腹尸检,使用总GLP-1ELISA(7-36和9-36)检测试剂盒(Alpco,43-GPTHU-E01)定量血浆总GLP-1浓度。
如图7所确认,在单独施用化合物1或二甲双胍的小鼠中未发现GLP-1分泌的显著增加。然而,与单独施用每种药物相比,当共同施用两种药物时,确认了总GLP-1血液浓度显著增加,从而实现药物组合增加GLP-1分泌的协同效应。
如图8所确认,当向小鼠单独施用每种药物时,空腹血糖水平有轻微降低的趋势。然而,当向小鼠共同施用两种药物时,表现出显著的空腹降血糖效果。换言之,共同施用的药效存在协同增强。
如图9所确认,当向小鼠单独施用化合物1和二甲双胍2周时,分别有-4.0%和-4.4%的体重减轻。相反,当向小鼠同时施用两种药物2周时,有-16.3%的体重减轻。换言之,与单独施用每种药物时相比,当向小鼠共同施用两种药物时,确认了对药物的反应性显著增加。由此确认,两种药物的共同施用对于肥胖的预防或治疗具有协同效应。
参考图9中施用结束3周后进行的身体成分分析的结果,当向小鼠单独施用化合物1两周时,没有降低体脂的效果。当向小鼠单独施用二甲双胍2周时,减少体脂的效果不显著。然而,当向小鼠共同施用两种药物时,确认了体脂的减少率为约30%。换言之,当向小鼠共同施用两种药物时,确认了不仅有降血糖效果,而且还有降低体脂效果。由此确认,两种药物的共同施用对于肥胖的预防或治疗具有协同效应。
<实施例5>GPR119配体与α-葡萄糖苷酶抑制剂的组合功效的确认
向禁食至少16小时的8周龄ICR雄性小鼠单独或组合口服施用3mg/kg的化合物1和0.02mg/kg的作为α-葡萄糖苷酶抑制剂的伏格列波糖。在30分钟后的时间点,以2g/kg/10ml口服加载蔗糖溶液。为了评价药物对餐后血糖水平的反应,在血液中葡萄糖注入后0、15、30、60、90和120分钟的时间点,使用Roche的AccuChek Active血糖仪测量从尾静脉收集的全血中的血糖水平。获得时间-血糖水平反应曲线。对于变化率,比较了仅施用溶剂的对照组的时间-血糖水平曲线下面积与药物施用组的时间-血糖水平曲线下面积。
如图10所确认,当向小鼠单独施用伏格列波糖时,没有降血糖效果。然而,与单独施用化合物1时相比,当向小鼠共同施用化合物1和伏格列波糖时,有更大的增加降血糖功效的协同效应。
Claims (14)
1.一种用于预防或治疗糖尿病或选自与之相关的代谢疾病的至少一种疾病的药物组合物,其包含由以下化学式1表示的化合物、其药学上可接受的盐、其旋光异构体、其水合物、其溶剂化物或其混合物,和选自DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种:
[式1]
其中在上式1中,
A为噁二唑基、二氢噁唑基、噻唑基或噻二唑基,其中以上A为未取代的或被选自以下的至少一个取代基取代:卤素原子、C1-C6直链或支链烷基和C1-C6直链或支链羟烷基,其中所述烷基或羟烷基各自独立地为未取代的或被卤素原子或C1-C6烷氧基取代;
B为吡啶基、嘧啶基、吡嗪基或噁二唑基,其中以上B为未取代的或被选自以下的至少一个取代基取代:卤素原子、C1-C6直链或支链烷基、C1-C6直链或支链羟烷基、C1-C6烷氧基和噁二唑基,其中所述C1-C6直链或支链烷基、C1-C6直链或支链羟烷基、C1-C6烷氧基或噁二唑基各自独立地为未取代的或被卤素、C1-C6烷基或C1-C6烷氧基取代;并且
X1和X2各自独立地为F、Cl、Br或I。
4.根据权利要求1所述的药物组合物,其中X为F。
5.根据权利要求1所述的药物组合物,其中以上A为被C1-C6直链或支链烷基取代的噁二唑基,以上B为被C1-C6直链或支链烷基取代的嘧啶基,并且X为F。
6.根据权利要求1所述的药物组合物,其中由上式1表示的化合物为3-(4-(3-(1-(5-乙基嘧啶-2-基)哌啶-4-基)丙氧基)-2,6-二氟苯基)-5-异丙基-1,2,4-噁二唑。
7.根据权利要求6所述的药物组合物,其中所述药物组合物包含DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种。
8.根据权利要求6所述的药物组合物,其中所述药物组合物包含依格列汀、西格列汀、埃拉贝诺、达格列净、格列美脲、二甲双胍和伏格列波糖中的至少一种。
9.根据权利要求1所述的药物组合物,其中所述药物组合物包含DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种。
10.根据权利要求9所述的药物组合物,其中所述药物组合物包含依格列汀、西格列汀、埃拉贝诺、达格列净、格列美脲、二甲双胍和伏格列波糖中的至少一种。
11.根据权利要求1所述的药物组合物,其中所述代谢疾病为肥胖和血脂异常中的至少一种。
12.药物组合物用于预防或治疗糖尿病或选自与之相关的代谢疾病的至少一种疾病的用途,所述药物组合物包含根据权利要求1所述的由式1表示的化合物、其药学上可接受的盐、其旋光异构体、其水合物、其溶剂化物或其混合物,和选自DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种。
13.药物组合物在制备用于预防或治疗糖尿病或选自与之相关的代谢疾病的至少一种疾病的药物制剂中的用途,所述药物组合物包含根据权利要求1所述的由式1表示的化合物、其药学上可接受的盐、其旋光异构体、其水合物、其溶剂化物或其混合物,和选自DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种。
14.一种用于预防或治疗糖尿病或选自与之相关的代谢疾病的至少一种疾病的方法,其包括向需要治疗的受试者施用治疗有效量的药物组合物,所述药物组合物包含根据权利要求1所述的由式1表示的化合物、其药学上可接受的盐、其旋光异构体、其水合物、其溶剂化物或其混合物,和选自DPPIV抑制剂、PPAR激动剂、SGLT2抑制剂、胰岛素促分泌素、双胍药物和α-葡萄糖苷酶抑制剂中的至少一种。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200030424 | 2020-03-11 | ||
KR10-2020-0030424 | 2020-03-11 | ||
PCT/KR2021/002990 WO2021182877A1 (ko) | 2020-03-11 | 2021-03-10 | 당뇨 및 이에 동반하는 대사 질환의 예방 또는 치료를 위한 약학적 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115243689A true CN115243689A (zh) | 2022-10-25 |
Family
ID=77671854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180019079.0A Pending CN115243689A (zh) | 2020-03-11 | 2021-03-10 | 用于预防或治疗糖尿病和与之相关的代谢疾病的药物组合物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230143119A1 (zh) |
EP (1) | EP4098262A4 (zh) |
JP (1) | JP7446465B2 (zh) |
KR (1) | KR102538048B1 (zh) |
CN (1) | CN115243689A (zh) |
AU (1) | AU2021235294B2 (zh) |
BR (1) | BR112022017942A2 (zh) |
CA (1) | CA3167630A1 (zh) |
IL (1) | IL295948A (zh) |
MX (1) | MX2022011129A (zh) |
WO (1) | WO2021182877A1 (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101128192A (zh) * | 2005-01-10 | 2008-02-20 | 艾尼纳制药公司 | 用于治疗糖尿病和其相关病状以及用于治疗通过增加血液glp-1水平而改善的病状的组合疗法 |
US20120053180A1 (en) * | 2010-08-27 | 2012-03-01 | Chemizon, A Division Of Optomagic Co., Ltd. | Cyclohexane analogues as gpr119 agonists |
US20140051714A1 (en) * | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
CN106459170A (zh) * | 2014-04-07 | 2017-02-22 | 赛诺菲 | 衍生自毒蜥外泌肽‑4的glp‑1/胰高血糖素受体双重激动剂 |
CN107074838A (zh) * | 2014-10-27 | 2017-08-18 | 东亚St株式会社 | 具有gpr119激动剂活性的化合物、制备其的方法和包含其作为有效组分的药物组合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
WO2008130584A1 (en) * | 2007-04-20 | 2008-10-30 | Schering Corporation | Pyrimidinone derivatives and methods of use thereof |
WO2016068453A1 (en) * | 2014-10-27 | 2016-05-06 | Dong-A St Co., Ltd. | Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component |
EP3391052A4 (en) * | 2015-12-16 | 2019-06-19 | Merck Sharp & Dohme Corp. | METHOD FOR PREVENTING OR TREATING HYPOGLYKEMIA BY ADMINISTERING A GPR119 AGONIST |
RU2768943C1 (ru) * | 2018-09-12 | 2022-03-25 | Тон-А Ст Ко., Лтд. | Фармацевтическая композиция для предупреждения или лечения неалкогольной жировой инфильтрации печени, содержащая лиганд gpr119 в качестве активного ингредиента |
-
2021
- 2021-03-10 CA CA3167630A patent/CA3167630A1/en active Pending
- 2021-03-10 BR BR112022017942A patent/BR112022017942A2/pt unknown
- 2021-03-10 IL IL295948A patent/IL295948A/en unknown
- 2021-03-10 US US17/905,918 patent/US20230143119A1/en active Pending
- 2021-03-10 KR KR1020210031531A patent/KR102538048B1/ko active IP Right Grant
- 2021-03-10 CN CN202180019079.0A patent/CN115243689A/zh active Pending
- 2021-03-10 MX MX2022011129A patent/MX2022011129A/es unknown
- 2021-03-10 WO PCT/KR2021/002990 patent/WO2021182877A1/ko unknown
- 2021-03-10 AU AU2021235294A patent/AU2021235294B2/en active Active
- 2021-03-10 EP EP21768861.3A patent/EP4098262A4/en active Pending
- 2021-03-10 JP JP2022554634A patent/JP7446465B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101128192A (zh) * | 2005-01-10 | 2008-02-20 | 艾尼纳制药公司 | 用于治疗糖尿病和其相关病状以及用于治疗通过增加血液glp-1水平而改善的病状的组合疗法 |
US20120053180A1 (en) * | 2010-08-27 | 2012-03-01 | Chemizon, A Division Of Optomagic Co., Ltd. | Cyclohexane analogues as gpr119 agonists |
US20140051714A1 (en) * | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
CN106459170A (zh) * | 2014-04-07 | 2017-02-22 | 赛诺菲 | 衍生自毒蜥外泌肽‑4的glp‑1/胰高血糖素受体双重激动剂 |
CN107074838A (zh) * | 2014-10-27 | 2017-08-18 | 东亚St株式会社 | 具有gpr119激动剂活性的化合物、制备其的方法和包含其作为有效组分的药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
KR20210114888A (ko) | 2021-09-24 |
AU2021235294A1 (en) | 2022-09-08 |
JP7446465B2 (ja) | 2024-03-08 |
KR102538048B1 (ko) | 2023-05-30 |
IL295948A (en) | 2022-10-01 |
JP2023517612A (ja) | 2023-04-26 |
CA3167630A1 (en) | 2021-09-16 |
AU2021235294B2 (en) | 2024-05-30 |
BR112022017942A2 (pt) | 2023-01-17 |
MX2022011129A (es) | 2022-10-13 |
US20230143119A1 (en) | 2023-05-11 |
WO2021182877A1 (ko) | 2021-09-16 |
EP4098262A4 (en) | 2024-02-28 |
EP4098262A1 (en) | 2022-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013540801A (ja) | 代謝異常の治療のための組合せ医薬 | |
KR20090088854A (ko) | 2-6-(3-아미노-피페리딘-엘-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸-4-플루오로-벤조니트릴의 용도 | |
BRPI0620450A2 (pt) | inibidor de dpiv para uso em combinação com metformina ou uma tiazolidinadiona e uso do referido inibidor | |
KR20150013838A (ko) | 당뇨병 치료를 위한 글루코키나아제 활성화제 조성물 | |
JP2015516404A (ja) | 代謝疾患の処置のための合剤 | |
JP2021534236A (ja) | 新規発症2型糖尿病の発生遅延並びに2型糖尿病の進行緩徐化及び治療の方法 | |
AU2019337286B2 (en) | Pharmaceutical composition for preventing or treating nonalcoholic fatty liver disease, containing GPR119 ligand as active ingredient | |
KR102538048B1 (ko) | 당뇨 및 이에 동반하는 대사 질환의 예방 또는 치료를 위한 약학적 조성물 | |
RU2809286C9 (ru) | Фармацевтическая композиция для предупреждения или лечения диабета и связанных с ним метаболических заболеваний | |
RU2809286C1 (ru) | Фармацевтическая композиция для предупреждения или лечения диабета и связанных с ним метаболических заболеваний | |
RU2803733C1 (ru) | Фармацевтическая композиция для предупреждения или лечения неалкогольного стеатогепатита | |
JP7469499B2 (ja) | 非アルコール性脂肪性肝炎の予防または治療用の薬学的組成物 | |
JP2012092038A (ja) | 糖尿病、糖尿病関連疾患又は糖尿病性合併症の予防又は治療剤 | |
WO2024055932A1 (zh) | 氮杂环化合物、其药物组合物和用于预防和/或治疗疾病的用途 | |
CN114794487A (zh) | 一种治疗糖尿病的方法 | |
KR20220166393A (ko) | 신규한 헤테로사이클릴-페닐-메틸아민 유도체, 이의 제조방법 및 이의 다발성 경화증 예방, 개선, 또는 치료 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40075147 Country of ref document: HK |